Cardiology

  • A link between A-fib and sleep apnea is no surprise, but why?
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine November 2019, 86 (11) 706-707; DOI: https://doi.org/10.3949/ccjm.86b.11019

    The two conditions commonly coexist, and treating the sleep apnea results in better rhythm-directed outcomes in the A-fib.

  • Should I evaluate my patient with atrial fibrillation for sleep apnea?
    Mirna B. Ayache, MD, MPH, Reena Mehra, MD, MS, FCCP, FAASM and Kenneth A. Mayuga, MD, FACC, FHRS
    Cleveland Clinic Journal of Medicine November 2019, 86 (11) 709-712; DOI: https://doi.org/10.3949/ccjm.86a.19033

    Yes. The prevalence of sleep apnea is high in patients with atrial fibrillation, and vice versa.

  • A complication of enoxaparin injection
    Ahmad Muneer Sharayah, MD, Samrah Zaigham, MD, Noor Hajjaj, MD and Mihir Maniar, DO
    Cleveland Clinic Journal of Medicine October 2019, 86 (10) 648-649; DOI: https://doi.org/10.3949/ccjm.86a.19026

    Computed tomography revealed a hematoma measuring 15 by 15 cm compressing the bladder and causing hydronephrosis.

  • 2019 Update in perioperative cardiovascular medicine
    Steven L. Cohn, MD, MACP, SFHM, Paul J. Grant, MD, SFHM, FACP and Barbara Slawski, MD, MS, SFHM
    Cleveland Clinic Journal of Medicine October 2019, 86 (10) 677-683; DOI: https://doi.org/10.3949/ccjm.86a.19077

    Studies of preoperative cardiac risk assessment, perioperative medication management, and postoperative complications.

  • Cardiovascular complications of systemic sclerosis: What to look for
    Cardiovascular complications of systemic sclerosis: What to look for
    Preethi Mani, MD, Danny Gonzalez, MD, Soumya Chatterjee, MD, MS, FRCP and Michael D. Faulx, MD
    Cleveland Clinic Journal of Medicine October 2019, 86 (10) 685-695; DOI: https://doi.org/10.3949/ccjm.86a.18109

    Pulmonary arterial hypertension, atherosclerosis, heart failure, arrhythmias, pericardial disease, and valvular heart disease.

  • Clinical outcomes in diabetes: It’s not just the glucose (and it’s not so simple)
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 573-574; DOI: https://doi.org/10.3949/ccjm.86b.09019

    As we dig deeper into the reduction in cardiovascular deaths seen with some newer drugs, several questions arise.

  • A young man with acute chest pain
    Amir Farid, MD, Neil Beri, MD, David Torres-Barba, MD, PhD and Charles Whitcomb, MD
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 586-594; DOI: https://doi.org/10.3949/ccjm.86a.19025

    A young man presents with severe, pressure-like, midsternal, nonradiating pain, rated 10 on a scale of 10.

  • ACE inhibitors and ARBs: Managing potassium and renal function
    Tasnim Momoniat, MBCHB, MRCP (UK), Duha Ilyas, MBBS, MRCP (UK) and Sunil Bhandari, MBCHB, FRCP, PhD, M CLIN EDU, FHEA
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 601-607; DOI: https://doi.org/10.3949/ccjm.86a.18024

    Concern about hyperkalemia and a decline in renal function has led to underuse of these drugs.

  • ACE inhibitor and ARB therapy: Practical recommendations
    Hernan Rincon-Choles, MD, MS
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 608-611; DOI: https://doi.org/10.3949/ccjm.86a.19016

    Inhibitors of the renin-angiotensin-aldosterone system are cornerstones of therapy of cardiovascular disease.

  • Disparities in cardiovascular care: Past, present, and solutions
    Quentin R. Youmans, MD, Lindsey Hastings-Spaine, MD, Oluseyi Princewill, MD, MPH, Titilayo Shobayo, BS and Ike S. Okwuosa, MD
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 621-632; DOI: https://doi.org/10.3949/ccjm.86a.18088

    Cardiovascular disease makes no distinction in race, sex, age, or socioeconomic status, and neither should clinicians.

Pages